Zobrazeno 1 - 10
of 40
pro vyhledávání: '"M. T. Caulier"'
Autor:
Laurent Decuypere, Bertrand Godeau, Philippe Bierling, Christian Rose, M. T. Caulier, Annette Schaeffer
Publikováno v:
British Journal of Haematology. 107:716-719
Since the first reports demonstrating the ability of a total dose of 2 g/kg body weight (b.w.) of intravenous immunoglobulin (IVIg) to increase the platelet count in patients with autoimmune thrombocytopenic purpura (AITP), the optimal dose has remai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb2cdd28ccb70b502ea34c8201f45f84
https://doi.org/10.1046/j.1365-2141.1999.01766.x
https://doi.org/10.1046/j.1365-2141.1999.01766.x
Autor:
Francis Bauters, Nathalie Cambier, Pierre Fenaux, Daniele Sautiere, Eric Wattel, M. T. Caulier
Publikováno v:
British Journal of Haematology. 87:205-208
Twenty patients with myelodysplastic syndromes (MDS) and (i) platelets < 50 x 10(9)/l and (ii) bone marrow blasts < or = 10% were treated with androgen therapy (fluoxymesterone at 1 mg/kg/d: seven patients; danazol at 600 mg/d: 13 patients) for at le
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c383ffa9b7c6db310bf4fac0c426a1fc
https://doi.org/10.1111/j.1365-2141.1994.tb04895.x
https://doi.org/10.1111/j.1365-2141.1994.tb04895.x
Autor:
P E Williams, I. Andresen, I Sklenar, M. Borte, W Egner, S. V. Davies, C. Adams, P Späth, H H Wolf, A. Morell, M T Caulier, H V Bernuth
Publikováno v:
Vox sanguinis. 84(1)
A nanofiltration step with the capacity to reduce blood-borne pathogens was introduced into the manufacturing process of intravenous immunoglobulin (IVIG). In order to demonstrate the efficacy, safety and pharmacokinetics of the modified product, we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65d9fef09d83a2649704dcede7b4d88c
https://pubmed.ncbi.nlm.nih.gov/12542733
https://pubmed.ncbi.nlm.nih.gov/12542733
Autor:
Christian Rose, Emmanuelle Bourgeois, Brigitte Dupriez, Francis Bauters, M T Caulier, Pierre Fenaux
Publikováno v:
Leukemia. 15(6)
Thrombocytopenia is generally of central origin in MDS, but can be due to peripheral platelet destruction in some cases. We studied platelet lifespan in 61 MDS cases with platelets70,000/mm3 and marrow blasts10%. Nine of them (15%) had a major platel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1025eb361c515b30d259eb8b3c10801
https://pubmed.ncbi.nlm.nih.gov/11417482
https://pubmed.ncbi.nlm.nih.gov/11417482
Publikováno v:
Journal des maladies vasculaires. 25(5)
Patients with polycethemia vera (PV) or essential thrombocythemia (ET) are at increased risk of arterial and venous thromboembolic events. Arterial ischemic complications occur in 24 to 43% of these patients, particularly those with cardiovascular ri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::029824316834c4a78bbdf1eac4fb707c
https://pubmed.ncbi.nlm.nih.gov/11148402
https://pubmed.ncbi.nlm.nih.gov/11148402
Publikováno v:
British journal of haematology. 107(4)
Since the first reports demonstrating the ability of a total dose of 2 g/kg body weight (b.w.) of intravenous immunoglobulin (IVIg) to increase the platelet count in patients with autoimmune thrombocytopenic purpura (AITP), the optimal dose has remai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4d50d0c27cb2c83ffca82561a949cd03
https://pubmed.ncbi.nlm.nih.gov/10606875
https://pubmed.ncbi.nlm.nih.gov/10606875
Autor:
Bertrand Godeau, Annette Schaeffer, Philippe Bierling, JM Vantelon, O. Tournilhac, Marc Ruivard, M. T. Caulier
Publikováno v:
British journal of haematology. 105(4)
The response to high-dose intravenous immunoglobulin (IVIg) was recently reported to be predictive of outcome after splenectomy in patients with autoimmune thrombocytopenic purpura (AITP). We analysed the records of 75 adults with chronic AITP who re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f458ea3f2b6115af12abaeebc97e9b3
https://pubmed.ncbi.nlm.nih.gov/10554833
https://pubmed.ncbi.nlm.nih.gov/10554833
Autor:
Pierre Fenaux, Eric Wattel, Francis Bauters, Dominique Bordessoule, Jean-Loup Demory, Yvon Sterkers, Jean-Luc Laï, Claude Preudhomme, M. T. Caulier
Publikováno v:
Blood
Blood, American Society of Hematology, 1998, 91 (2), pp.616-22
ResearcherID
Europe PubMed Central
Blood, American Society of Hematology, 1998, 91 (2), pp.616-22
ResearcherID
Europe PubMed Central
Treatment with alkylating agents or radiophosphorous (32P) has been shown to carry a certain leukemogenic risk in myeloproliferative disorders (MPDs), including essential thrombocytemia (ET). The leukemogenic risk associated to treatment with hydroxy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f6381cd7bf1f5100e7f66099b0c0a3c
https://hal.umontpellier.fr/hal-02505375
https://hal.umontpellier.fr/hal-02505375
Autor:
Damien Huglo, T. Prangère, R. D. Pickett, V. Beauchat, M. T. Caulier, A. D. Bowden, P. Ziegels, Marc Steinling
Publikováno v:
Nuclear medicine communications. 18(3)
The method described by Weisner et al. for stabilizing 99Tcm-hexamethylpropylene amine oxime ( 99 Tc m -HMPAO) with cobalt chloride hexahydrate solution is the most promising developed to date. The aim of our work was to study the behaviour of cobalt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93ccc836b582c75d69d2f0602725b47e
https://pubmed.ncbi.nlm.nih.gov/9106780
https://pubmed.ncbi.nlm.nih.gov/9106780
Autor:
Marc Wetterwald, Pierre Fenaux, M. T. Caulier, M Hebbar, Francis Bauters, Pierre Morel, C. Kaplan, Eric Wattel
Publikováno v:
British journal of haematology. 94(1)
We prospectively studied the mechanism of thrombocytopenia in 30 patients with myelodysplastic syndrome (MDS), who had a platelet count
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aef4e8d137a40dbac26148badfcf8dff
https://pubmed.ncbi.nlm.nih.gov/8757517
https://pubmed.ncbi.nlm.nih.gov/8757517